Design: In a retrospective cohort study, patients with transfusionrelated acute lung injury were identified using the consensus criteria of acute lung injury within 6 hrs after transfusion. Inclusion criterion was a length of intensive care unit admission >48 hrs. Patients developing transfusion-related acute lung injury were matched (on age, sex, and admission diagnosis) to transfused control subjects and patients developing acute lung injury from another origin. 
T ransfusion-related acute lung injury (TRALI) is the most serious cause of transfusionrelated morbidity and mortality (1) (2) (3) . Incidence reports on TRALI vary widely, ranging from 0.08% to 8% per transfused patient (4 -6) . Variance in incidence may be explained by differences in case definition, patient population, and study design. In an effort to enhance comparability of epidemiologic data, a case definition was developed, in which TRALI is defined as acute lung injury (ALI) developing within 6 hrs after transfusion in the absence of an other risk factor for ALI (1, 3, 7) . Possible TRALI is diagnosed when a risk factor for ALI is present before transfusion. Using the consensus definition, TRALI incidence was reported to be high in a critically ill patient population in the United States (4) . In Europe, estimates of incidence are limited to passive reports of national blood banks (8 -10) . No European data are present on the incidence of TRALI in critically ill patients.
Risk factors for the onset of TRALI are largely unknown. TRALI is postulated to be a two-event syndrome. The "first hit" is the underlying clinical condition, causing priming of the neutrophils in the pulmonary capillaries. The "second hit" is the transfusion of either antibodies or bioactive lipids that have accumulated during storage of cell-containing blood products resulting in activation of the primed neutrophils and subsequent pulmonary leakage (5, 11) . In line with this hypothesis, a TRALI threshold model has been postulated, in which the onset of TRALI depends both on the severity of the underlying condition and on the severity of the transfusion mediator (antibody titer or concentration of bioactive lipids) (12) . Because critically ill patients often have an underlying condition that may prime the neutrophils, the two-event model of TRALI may account for the high incidence of TRALI in this population (4, 13) . In accordance, sepsis is a risk factor for TRALI (4) . Whether other established risk factors for ALI also apply to TRALI is unknown. Knowledge of risk factors may help to identify patients at risk for TRALI, thereby assessing risks and benefits of a blood transfusion.
It is generally stated that TRALI has a good prognosis (1, 7, 14) . However, this is based on a relatively small case series (6, 15) and may not be true for critically ill patients. Transfusion in the critically ill is associated with onset of ALI and with mortality (4, 13, 16 -18) . Although the timeframe in most of these studies was not determined, some of these patients may have had TRALI. In accordance, a restrictive transfusion policy is associated with fewer pulmonary complications and lower mortality rates (19, 20) . However, data on outcome of TRALI in the critically ill patient population are largely absent.
To investigate incidence, risk factors, and outcome of TRALI and their relation to ALI from other etiologies, we performed a retrospective case-control study in a cohort of patients in our intensive care unit (ICU) using the consensus TRALI definition.
MATERIALS AND METHODS
Setting. The study was performed in a 30-bed mixed medical-surgical intensive care unit (ICU) of a university hospital in The Netherlands. The ICU is a "closed format" department in which patients are under the direct care of the ICU team consisting of intensivists, subspecialty fellows, and residents.
Design. The study was approved by the Ethics Committee of our hospital. Using an electronic patient data monitoring system, all patients admitted to our ICU from November 1, 2004, until October 1, 2007, were screened ( Fig. 1) for onset of TRALI. Patients who were readmitted were excluded. In previous studies, patients developing TRALI had a length of ICU admission of at least 48 hrs (4, 13) . Therefore, patients with a length of stay Ͻ48 hrs were excluded. Not to miss significant TRALI cases by excluding this group, patients who died within 48 hrs of admission were screened as well for onset of TRALI. Patients with suspected TRALI who had died within 48 hrs of admission were taken into account for incidence analysis but were excluded for risk factor analysis. For risk factor analysis, each suspected or possible TRALI case was matched with control subjects on sex, age (Ϯ10 yrs), and admission diagnosis. Control subjects were transfused patients not developing ALI, patients not transfused developing ALI, and patients not transfused not developing ALI.
Suspected TRALI was defined using the consensus definition of ALI (new-onset hypoxemia or deterioration demonstrated by a PaO 2 / FIO 2 Ͻ300 mm Hg within 6 hrs after transfusion with bilateral pulmonary changes in the absence of cardiogenic pulmonary edema) (1, 3, 7) . Possible TRALI was defined as TRALI in the presence of an alternative risk factor for ALI. Cardiogenic pulmonary edema was identified when pulmonary arterial occlusion pressure was Ͼ18 mm Hg or by the presence of at least two of the following; central venous pressure Ͼ15 mm Hg, a history of heart failure or valve dysfunction, ejection fraction Ͻ45% as estimated by echocardiogram, and a positive fluid balance. The probability of cardiogenic pulmonary edema was scored by two independent physicians on a 1 to 4 scale (21). Chest radiographs were scored for the presence of new-onset bilateral interstitial abnormalities by two independent physicians who were blinded to the predictor variables. When interpretation differed, chest radiograph and the description by the radiologist were reviewed to reach consensus.
Patient Data Collection. The National Intensive Care Evaluation (NICE) (22, 23) minimal data set prospectively collects data to calculate the Acute Physiology and Chronic Health Evaluation (APACHE II) score as well as information on referring specialist, length of stay, and mortality (24) . Potential risk factors were scored as positive when present 48 hrs before onset of TRALI. Factors included alcohol abuse, smoking, liver failure, diabetes, hematologic malignancy, chronic obstructive pulmonary disease, autoimmune disease, immune compromised condition, massive transfusion, elective cardiac surgery, trauma, emer- (27) .
Statistics. Continuous normally distributed variables were expressed as mean and SD or SEM and nonnormally distributed variables as medians and interquartile ranges. Categorical variables were expressed as n (%). To test groups of continuous normally distributed variables, Student's t test was used or, when more than two independent groups were involved, analysis of variance was used. Likewise, if continuous data were not normally distributed, the Mann-Whitney U test was used or the Kruskal-Wallis test to compare three or more groups. Categorical variables were compared with the chi-square test or Fisher's exact tests when appropriate.
Univariable analyses examined the effect of patient clinical characteristics on outcome (TRALI, ALI, no ALI) of transfused and nontransfused patients. Thereafter, multiple logistic regression, using the Enter method, was applied to the outcomes. Factors achieving p Յ .10 in our univariable analyses and factors deemed clinically relevant were entered into the models predicting the risk for the onset of TRALI or ALI. The final multivariable model was evaluated for calibration using the Hosmer-Lemeshow goodness-of-fit statistic (where p Ͼ .05 indicates good fit). The variables in the multivariate analyses were checked for multicollinearity by calculating the variance inflation factor.
We analyzed the association between TRALI and control subjects (no ALI transfused and ALI no transfusion) and time to death adjusted for severity of illness with Cox's proportional hazards model. The hazard ratio is reported with 95% confidence limits.
Statistical significance was defined as p Յ .05. Analyses were performed using SPSS 15.0 software (SPSS, Chicago, IL).
RESULTS
During the screening period, 5208 patients were admitted to our ICU. Of these admissions, 353 patients were readmissions, and 2831 were discharged from the ICU within 48 hrs (Fig. 1) . The interobserver agreement for the diagnosis of ALI was good (weighed kappa 0.61).
Incidence
Of 5208 admitted patients, 114 patients confirmed to the diagnostic criteria for TRALI (with or without a risk factor for ALI present). Of these, 100 (87%) patients had a risk factor for ALI before onset of TRALI (possible TRALI). Of 5208 admitted patients, 2235 patients were transfused. In total, 12,832 blood products were transfused. The transfused products consisted of 7570 units RBCs, 3942 units FFP, and 1211 units platelet concentrates. The incidence of TRALI was 0.9% (114 of 12,832) per unit transfused. The incidence of suspected TRALI cases in the screened cohort was 2.2% (114 of 5208). The incidence per transfused patient was 5.1% (114 of 2235). Of the 114 patients, 5 patients died within 48 hrs after admission. In 2024 patients with a length of stay Ͼ48 hrs, 109 patients developed ALI within 6 hrs after a blood transfusion. Risk factors for onset of TRALI were evaluated in the 109 patients with TRALI with a length of stay Ͼ48 hrs.
Patient-related Risk Factors
TRALI vs. Transfused Control Subjects. Compared with transfused control subjects, patients developing TRALI had a higher APACHE II score, a higher incidence of hematologic malignancy, had higher incidence of sepsis, were mechanically ventilated more frequently, were massively transfused more frequently, and underwent emergency coronary artery bypass grafting more often (Table 1) . Patients developing TRALI had a lower platelet and leukocyte count before transfusion compared with transfused control subjects. In accordance with the onset of disease, transfusion resulted in worsening of the lung compliance of patients with TRALI compared with transfused control subjects. Fluid balance was similar in patients developing TRALI compared with transfused control subjects. Multivariate logistic regression analysis showed that high APACHE II score, hematologic malignancy, sepsis, mechanical ventilation, massive transfusion, and emergency coronary artery bypass grafting are risk factors for the development of TRALI (Table 2) .
TRALI vs. ALI Resulting From Other Etiologies. Compared with ALI control subjects, patients developing TRALI had a higher APACHE II score, a higher incidence of hematologic malignancy, a higher incidence of sepsis, and a higher incidence of disseminated intravascular coagulation (Table 1) . Patients with ALI resulting from other causes more often had pneumonia and more often received mechanical ventilation before onset compared with patients with TRALI. Patients developing TRALI had a lower platelet and leukocyte counts before transfusion. Lung compliance was low in both groups. However, after onset of ALI, lung compliance was worse in patients with TRALI compared with nontransfused patients with ALI. Multivariate logistic regression analysis showed that high APACHE II score and sepsis were risk factors for developing TRALI compared with patients developing ALI resulting from other etiologies (Table 2 ). Pneumonia was a risk factor for developing ALI in the absence of transfusion compared with patients developing TRALI.
TRALI or ALI vs. Conrol Subject. Multivariate logistic regression analysis of risk factors to develop ALI from any kind of origin (both transfusion and ALI resulting from other etiologies grouped together) compared with control subjects (no ALI) were high APACHE II score, hematologic malignancy, sepsis, massive transfusion, mechanical ventilation, and emergency coronary artery bypass grafting (Table 2 ). Diabetes was a negative factor for developing ALI from any origin compared with control subjects.
For the three previously reported multiple logistic regression models, we evaluated the model fit by the Hosmer-Lemeshow goodness of fit, which showed p ϭ .11, p ϭ .25, and p ϭ .65, respectively. Furthermore, colinearity for each model was checked by the variance inflation factor and showed variance inflation factors between 1.01 and 1.16 for all variables.
Transfusion-related Risk Factors
Amount of Blood Products. Patients developing TRALI received more units of platelet transfusions compared with transfused control subjects ( Table 3 ). The amount of FFP units transfused in the TRALI group did not differ from control subjects. However, patients developing TRALI received a larger volume of plasma (Table 3 ). The amount of RBC transfusions did not differ between patients with TRALI and transfused control subjects. Univariate analysis showed that the number of FFP and platelets and the volume of plasma transfused were associated with the onset of TRALI compared with transfused control subjects. In the multivariate analysis, however, transfusion-related risk factors were not significant.
Age of Blood Products. The mean storage time of RBCs did not differ between the TRALI and control groups (Table 3) (27) .
Outcome of Patients With TRALI
When adjusted for baseline APACHE II score, patients with TRALI had a longer length of ICU stay and were mechanically ventilated for longer periods of time compared with transfused control subjects (Table 4) . Cox regression analysis showed that survival adjusted for baseline APACHE II score was lower in the TRALI group compared with transfused control subjects (53% vs. 75%, p Ͻ .002). The hazard ratio was 1.05 (95 confidence limit, 1.02-1.08) for each single point change in APACHE II score, indicating that the underlying condition of the patients played a minor role in the discrepancy in survival between TRALI and transfused control subjects. Hematologic malignancies, sepsis, and massive transfusion occurred more frequently in the TRALI group than in the transfused control group. When analyzed separately, mortality in patients with hematologic malignancy, sepsis, and massively transfused patients was higher in the TRALI group (nine of 18 20 (18) 17 (16) 10 (9) Aspiration, n (%) 1 (1) 0 (0) 4 (4) 1 (1) Surgery, n (%) 29 (27) 22 (20) 20 (18) 26 (24) Trauma, n (%)
11 (10) 10 (9) 8 (7) 6 (6) Pancreatitis, n (%)
2 (2) TRALI was lower compared with patients with ALI resulting from other etiologies (53% vs. 83%, p Ͻ .02; Fig. 2 ). Adjusted lengths of ICU stay and lengths of mechanical ventilation of patients with TRALI were also longer compared with ALI as a result of other etiologies.
DISCUSSION
The present study reports a high incidence of suspected and possible TRALI in critically ill patients. Emergency coronary artery bypass grafting, sepsis, and hematologic malignancy were confirmed as risk factors for the onset of TRALI (4, 5, 13) . Additional risk factors were identified, including high APACHE II score, mechanical ventilation, and massive transfusion. Transfusion-related risk factors included the amount of plasma and platelets, but not the age of blood products. TRALI significantly contributed to morbidity and mortality in the critically ill.
Incidence. The incidence found in this study is higher compared with general incidence reports on TRALI (5, 6, 8, 10, 15, 28) . This may partly be explained by the inclusion method. Most reports are overviews of passive reporting to the National Hemovigilance System, whereas in our study, we actively searched for onset of ALI in relation to transfusion (6, 8, 10, 28) . Of note, in only three of the 114 TRALI cases, an association with the transfusion was noted by the treating physician, of which only one case was reported to the National Blood Bank. This confirms that TRALI is underrecognized and underreported. An alternative explanation for the higher incidence of TRALI found in this study compared with general incidence reports may be the "twohit" hypothesis, in which inflammatory conditions commonly found in the critically ill predispose for the occurrence of TRALI. In agreement, incidence was reported to be 8% in a critical ill patient population in the United States (4).
Patient-Related Risk Factors. In the present study, we confirm previously found patient risk factors and identify new risk factors. Interestingly, patientrelated risk factors are in line with the "two-hit" model of TRALI (29) as suggested by preclinical studies (30 -32) . All patient-related risk factors in the present study are characterized by a proinflammatory state with the potential to prime pulmonary neutrophils and to serve as a "first hit" in developing TRALI (5, 24, (33) (34) (35) (36) (37) . In accordance, although not meeting ALI criteria, lung compliance was already decreased before transfusion, which may suggest lung injury and pulmonary priming. After transfusion, lung compliance worsened and patients fulfilled ALI criteria. The importance of the presence of such a "first hit" is underscored by results from the multivariate analysis showing that patient-related risk factors were more important for the onset of TRALI than transfusion-related risk factors. In accordance, in experimental settings, a "first hit" is essential in developing TRALI both with antibody-containing plasma and with stored blood prod- ALI, acute lung injury; TRALI, transfusion-related acute lung injury; OR, odds ratio; APACHE, Acute Physiology and Chronic Health Evaluation; CABG, coronary artery bypass grafting. TRALI, transfusion-related acute lung injury; ALI, acute lung injury; RBC, red blood cells; FFP, fresh-frozen plasma; PLT, platelet concentrates.
Data are presented as mean Ϯ SEM.
ucts (30) . In line with this, patients developing TRALI in this study had higher APACHE II scores compared with patients developing ALI. It has been speculated that disease severity may contribute to a lower threshold to develop TRALI (12) . However, our results do not rule out that the blood transfusion is merely a marker of disease severity. To our knowledge, TRALI has not been compared with ALI as a result of other etiologies before. Interestingly, risk factor profiles of patients developing TRALI differ from patients developing ALI in the absence of a transfusion. TRALI seems to occur in patients with systemic diseases such as sepsis, whereas patients developing ALI in the absence of a transfusion are more likely to have local pulmonary "first hits" such as pneumonia. In sepsis, the endothelium is a key factor in initiating the inflammatory response, including leukocyte adhesion through upregulation of expression of adhesion molecules, resulting in strong adherence and transmigration of leukocytes into the lung (38) . Of note, in an experimental antibody-mediated TRALI model, organ damage was not confined to the respiratory system, but also included kidney and liver damage (39) . In conclusion, sepsis may predispose to TRALI through endovascular-mediated proinflammatory host responses that prime neutrophils.
Importantly, when the ALI and TRALI cohorts were taken together, analysis of risk factors showed comparable results with previous studies on ALI/acute respiratory distress syndrome (5, 36, 37, 40 -42) , which suggests a representative cohort of critically ill patients. However, when analyzed separately, our results suggested that established risk factors for ALI (e.g., massive transfusion, sepsis) may actually be risk factors for the onset of TRALI. These findings raise the question of whether TRALI should be regarded as a diagnosis after exclusion of other ALI risk factors. Rather, we suggest that TRALI may be viewed as an entity of the ALI spectrum.
Transfusion-Related Risk Factors. HLA antibodies in the transfused plasma have been implicated in TRALI. The female donor population has a higher incidence of these antibodies in their plasma as a result of sensitization during labor (43) . In accordance, we show that plasma transfusion is associated with the onset of TRALI as reported before (4, 13) . However, we found merely a modest trend for female donor involvement in the onset of TRALI. Unfortunately, we were not able to retrieve information on parity. However, when a period before exclusion of female donors for FFP donation (effective in The Netherlands as of June 1, 2007) was compared with the same time period after exclusion of female donors, a reduction of patients with TRALI was found (27) , consistent with another report with a similar investigational approach (44) . In addition, we found that the amount of platelets, which contained a high volume of plasma, was also associated with the onset of TRALI. Although there was an effect of plasma transfusion on the onset of TRALI in this cohort, other transfusion-related factors besides antibodies were likely to play a role. In accordance, excluding female donors reduced but did not prevent TRALI cases.
Transfusion of RBCs is associated with respiratory complications (45) (46) (47) (48) . We found no association between the amount of transfused units and the onset of TRALI, which is in accordance with previous data in critically ill patients (4, 13) . However, in line with previous reports, we did find that massive transfusion was a strong risk factor for the onset of TRALI (49, 50) . Possibly, previous studies did not differentiate between RBCs and other transfused blood products as causative in the onset of ALI. Alternatively, onset of TRALI may not occur exclusively within the defined 6-hr timeframe of the international consensus definition. However, we showed that using the consensus definition, TRALI contributed to adverse outcome unrelated to the amount of RBCs. Therefore, (the amount of) FFP or platelets may have had a stronger impact on the occurrence of TRALI than RBCs.
A topic that is currently receiving attention is the possible association between storage time and ALI. Experimental "twohit" models have used both stored RBCs and platelets to induce TRALI (30 -32 and critically ill patients showed conflicting results on the effects of aged RBCs (4, 13, 42, 46, 51, 52) . Our findings did not justify an adjustment of storage time of blood products for critically ill patients.
Outcome. In the critically ill, an association between transfusion and respiratory complications is apparent (5, 6, 13, 15) . The mechanism behind this association, however, is less clear. We show that TRALI is associated with increased morbidity and mortality also when adjusted for a baseline outcome predictor. This finding is in contrast with the frequently stated perception that TRALI has a good prognosis (1, 7, 14) . Of interest, survival curves begin to diverge beyond 3 wks. An explanation for this late mortality is speculative. Despite a low hazard ratio indicating a minor role for the underlying condition, the higher percentage of patients with hematologic malignancy in the TRALI group probably contributed to late mortality. Alternatively, it was shown previously that TRALI was not confined to the lung, but also resulted in liver and kidney injury (39) . Presumably, organ failure caused by TRALI may have contributed to late mortality.
Implications. Given the significant morbidity of TRALI in the critically ill, preventive measures need more attention. Our results support the relevance of strict transfusion triggers, particularly in patients with a high APACHE II scores, sepsis, hematologic malignancy, and emergency coronary artery bypass grafting. Other strategies to prevent TRALI may include excluding female donors for plasma and platelet concentrates. However, excluding females will probably not completely prevent TRALI. Also, excluding females may impair steady blood supply. Whether a differential manufacturing and transfusion policy for at-risk patients is a feasible measure to reduce the risk of TRALI remains to be determined.
Study Limitations. In critically ill patients, it is difficult to determine whether blood transfusion contributes to adverse outcome instead of merely being a consequence of anemia as part of an underlying disease. The majority of patients with TRALI in this study had an additional ALI risk factor. Our data do not show whether the transfusion or the other ALI risk factor contributed more to outcome. However, the comparison of TRALI with ALI resulting from other etiologies may give some proof that blood transfusion is a mediator of adverse outcome and not just a marker.
Using the case definition of TRALI may have resulted in diagnosing part of the TRALI cases as transfusion-associated cardiac overload or vice versa. However, diagnostic criteria were applied to each group in the same manner. Also, fluid balance of TRALI and transfused control subjects did not differ, and no signs of cardiogenic pulmonary edema were recorded in the clinical file. Finally, the retrospective design of the study may have resulted in neglecting unknown confounding factors.
CONCLUSION
The incidence of TRALI is high in the critically ill and significantly increases morbidity and mortality. The high incidence can be explained by an underlying systemic inflammatory condition of these patients and by transfusion of highvolume plasma products and platelet concentrates. We conclude that TRALI may contribute to an adverse outcome associated with blood transfusion. TRALI risk factors identified in this study may help learners assess the risks and benefits of transfusion of blood products.
